Cargando…

RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells

Rationale: PI3K/mTOR signaling is frequently upregulated in breast cancer making inhibitors of this pathway highly promising anticancer drugs. However, PI3K-inhibitors have a low therapeutic index. Therefore, finding novel combinatory treatment options represents an important step towards clinical i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hölzen, Lena, Mitschke, Jan, Schönichen, Claudia, Hess, Maria Elena, Ehrenfeld, Sophia, Boerries, Melanie, Miething, Cornelius, Brummer, Tilman, Reinheckel, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169373/ https://www.ncbi.nlm.nih.gov/pubmed/35673573 http://dx.doi.org/10.7150/thno.68299

Ejemplares similares

Degradome-focused RNA interference screens to identify proteases important for breast cancer cell growth
por: Hölzen, Lena, et al.
Publicado: (2022)

Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling
por: Ketterer, Stephanie, et al.
Publicado: (2020)

Dipeptidyl-Aminopeptidases 8 and 9 Regulate Autophagy and Tamoxifen Response in Breast Cancer Cells
por: Bettecken, Aaron, et al.
Publicado: (2023)

BRAF(V600E) drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation
por: Reischmann, Nadine, et al.
Publicado: (2020)

Protease Addiction and Synthetic Lethality in Cancer
por: Freije, José M. P., et al.
Publicado: (2011)

MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?
por: Zhang, Tingting, et al.
Publicado: (2020)

Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response
por: Kciuk, Mateusz, et al.
Publicado: (2022)

Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines
por: Boerries, Melanie, et al.
Publicado: (2015)

Genetic screening for anticancer genes highlights FBLN5 as a synthetic lethal partner of MYC
por: Masood, Motasim, et al.
Publicado: (2023)

Systems biology-guided identification of synthetic lethal gene pairs and its potential use to discover antibiotic combinations
por: Aziz, Ramy K., et al.
Publicado: (2015)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

Murine Oncostatin M Has Opposing Effects on the Proliferation of OP9 Bone Marrow Stromal Cells and NIH/3T3 Fibroblasts Signaling through the OSMR
por: Jakob, Lena, et al.
Publicado: (2021)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens
por: Christodoulou, Eleni G., et al.
Publicado: (2017)

On the road to inflammation: Linking lysosome disruption, lysosomal protease release and necrotic death of immune cells
por: Reinheckel, Thomas
Publicado: (2013)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro
por: Li, Jianfa, et al.
Publicado: (2019)

Specific functions of lysosomal proteases in endocytic and autophagic pathways()
por: Müller, Sabrina, et al.
Publicado: (2012)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models
por: Li, Jie, et al.
Publicado: (2023)

Low‐level lysosomal membrane permeabilization for limited release and sublethal functions of cathepsin proteases in the cytosol and nucleus
por: Reinheckel, Thomas, et al.
Publicado: (2022)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Protocol for Comprehensive Synthetic Lethality Screens
por: Romero-Moya, Damia, et al.
Publicado: (2020)

The tumor therapy landscape of synthetic lethality
por: Zhang, Biyu, et al.
Publicado: (2021)

Overview of Ferroptosis and Synthetic Lethality Strategies
por: Kinowaki, Yuko, et al.
Publicado: (2021)

Synthetic Lethality Targeting Polθ
por: Drzewiecka, Małgorzata, et al.
Publicado: (2022)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

Cationic polyamines inhibit anthrax lethal factor protease
por: Goldman, Mark Evan, et al.
Publicado: (2006)

Protease-Sensitive Synthetic Prions
por: Colby, David W., et al.
Publicado: (2010)

Development of Synthetic Lethality Anticancer Therapeutics: Miniperspective
por: Fang, Bingliang
Publicado: (2014)

Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015)

Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer
por: Ebeid, Kareem, et al.
Publicado: (2017)

Synthetic lethality: emerging targets and opportunities in melanoma
por: Thompson, Nicola, et al.
Publicado: (2017)

Epigenetic synthetic lethality approaches in cancer therapy
por: Yang, Haoshen, et al.
Publicado: (2019)

Synthetic Lethality through the Lens of Medicinal Chemistry
por: Myers, Samuel H., et al.
Publicado: (2020)

Breast Cancer Predisposition Genes and Synthetic Lethality
por: Neiger, Hannah E., et al.
Publicado: (2021)

Harnessing Synthetic Lethal Interactions for Personalized Medicine
por: Shieh, Grace S.
Publicado: (2022)

Rapid Inhibitor Discovery by Exploiting Synthetic Lethality
por: Muscato, Jacob D., et al.
Publicado: (2022)

Overcoming selection bias in synthetic lethality prediction
por: Seale, Colm, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cr99i6c4n64ia2ipihsqu3pp1h